- Neuroendocrine Cancer
- Newly Diagnosed
- Carcinoid & Neuroendocrine Tumor Patient Community
- Doctor Database
- Clinical Trials
- Educational Resources
- Additional Resources
- Join Us For a Cure
- Researching Funding Opportunities
- Current Research Grants
- Previous Research Grants
- Research Approach
- Board of Scientific Advisors
- About Us
- CFCF News
- Founder Nancy Lindholm
- Corporate Sponsorship
Large-Scale Genome Study
Action #3: Perform a Large-Scale Genome Study of Carcinoid
Fundraising Target: $1,500,000
A large-scale genome study promises to unlock many of carcinoid's mysteries.
Leading scientists funded by the Caring for Carcinoid Foundation have hypotheses about the genes that contribute to the growth and development of carcinoid. These genes may represent targets for novel, targeted therapies. Our next step is to perform a large-scale genome study of carcinoid and related NET to validate these hypotheses.
Large-scale genome studies are the centerpiece of cutting-edge cancer research. The National Cancer Institute (NCI) and National Human Genome Research Institute (NHGRI) are spearheading this effort. In December 2005, NCI and NHGRI launched a "comprehensive effort to accelerate our understanding of the molecular basis of cancer through the application of genome analysis technologies, especially large-scale genome sequencing." This joint effort is called The Cancer Genome Atlas.
According to Elias A. Zerhouni, M.D., Director of the National Institutes of Health (NIH):
"Now is the time to move forward with this pioneering initiative. Thanks to the tools and technologies developed by the Human Genome Project and recent advances in using genetic information to improve cancer diagnosis and treatment, it is now possible to envision a systematic effort to map the changes in the human genetic blueprint associated with all known forms of cancer.
This atlas of genomic changes will provide new insights into the biological basis of cancer, which in turn will lead to new tests to detect cancer in its early, most treatable stages; new therapies to target cancer at its most vulnerable points; and, ultimately, new strategies to prevent cancer."
It is urgent to perform a large-scale genome study to move rapidly toward better diagnosis, treatment, and prevention of carcinoid.
Our objective is to perform the world's first large-scale genome study of carcinoid:
- To diagnose carcinoid earlier
- To develop new, targeted therapies for carcinoid
- To prevent future occurrences of carcinoid
If we achieve our fundraising target of $1,500,000, we will issue a Research RFP to perform the large-scale genome study of carcinoid.
The Caring for Carcinoid Foundation has launched the first large-scale genome study of carcinoid tumors led by Dr. Matthew Meyerson, M.D., Ph.D., Director of the Center for Cancer Genome Discovery at Dana-Farber Cancer Institute, and Associate Professor of Pathology at Harvard Medical School. CFCF selected Dr. Meyerson's proposal for this project because he and his team of collaborators have consistently been at the forefront of genomics.